Variability of NT-proBNP levels in heart failure: Implications for clinical application

Heart

Volumn 93, Issue 8, 2007, Pages 899-900

  Richards, A Mark ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

BLOOD SAMPLING; CLINICAL TRIAL; DISEASE COURSE; ECHOCARDIOGRAPHY; EDITORIAL; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE VARIABILITY; HOSPITAL ADMISSION; HUMAN; IMMUNOASSAY; IMMUNOREACTIVITY; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; URINALYSIS;

AREA UNDER CURVE; BIOLOGICAL MARKERS; HEART FAILURE, CONGESTIVE; HUMANS; IMMUNOASSAY; METABOLIC CLEARANCE RATE; MORBIDITY; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 34547195382     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2006.110643     Document Type: Editorial

References (18)

1. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115- 40.
2. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001;37:386-91.
3. Bettencourt P, Azvedo A, Pimento J, et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004;110:2168-74.
4. Latini R, Masson S, Wong M, et al. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med 2006;119:70.e23-30.
5. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30.
6. Jourdain P, Funck F, Gueffet P, et al. Benefit of BNP plasma levels for optimising therapy: the Systolic Heart Failure Treatment Supported by BNP Multicenter Randomised Trial (STARS-BNP) [abstract]. J Am Coll Cardiol 2005;45(Suppl A):3A.
7. Shah M, STARBRITE Investigators. STARBRITE: a randomized pilot trial of BNP-guided therapy in patients with advanced heart failure [abstract]. Circulation 2006;114(suppl.II):II-528.
8. Cortes R, Rivera M, Salvador A, et al. Variability of NT-proBNP plasma and urine levels in patients with stable heart failure: a 2-year follow-up study. Heart 2007;93:957-62.
9. Wu AHB, Smith A, Wieczorek S, et al. Biological variation for N-terminal pro-and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 2003;92:628-31.
10. Wu AHB, Smith A. Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur J Heart Fail 2004;6:355-8.
11. Bruins S, Fokkema R, Römer JWP, et al. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 2004;50:2052-8.
12. Schou M, Gustafsson F, Nielsen PH, et al. Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state. Eur J Heart Fail 2007;9:68-74.
13. Troughton RW, Richards AM. BNP for clinical monitoring of heart failure. Heart Failure Clin 2006;2:333-43.
14. Lainchbury JG, Troughton RW, Frampton CM, et al. NTproBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial. Eur J Heart Fail 2006;8:532-8.
15. Clerico A, Zucchelli GC, Pilo A, et al. Clinical relevance of biological variation of B-type natriuretic peptide. Clin Chem 2005;51:925-6.
16. Ng LL, Geeranavar S, Jennings SC, et al. Diagnosis of heart failure using urinary natriuretic peptides. Clin Sci 2004;106:129-33.
17. Cortes R, Portolés M, Salvador A, et al. Diagnostic and prognostic value of urine NT-proBNP levels in heart failure patients. Eur J Heart Fail 2006;8:621-7.
18. Ng LL, Loke IW, Davies JE, et al. Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides. J Am Coll Cardiol 2005;45:1043-1050.